Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

This trial is for women with early-stage breast cancer that is hormone receptor-positive (responds to estrogen or progesterone) and HER2-negative. It focuses on a specific group: patients whose cancer looks high-risk based on clinical factors but low-risk based on genetic testing. The goal is to determine whether chemotherapy is truly needed for this group. **You may be eligible if...** - You are a woman aged 19–80 with invasive, hormone receptor-positive, HER2-negative breast cancer - Your tumor is at least 0.5 cm - You have zero or limited lymph node involvement - Your cancer scores as clinically high-risk but genomically low-risk based on specific testing (GenesWell BCT) - You have not had a previous invasive cancer **You may NOT be eligible if...** - You have metastatic (spread) disease - Your tumor does not meet the hormone receptor or HER2 criteria - You have already received treatment for this cancer Talk to your doctor to see if this trial is right for you.